Lorus announces down regulation of GTI-2040 molecular target in breast cancer clinical study
Publication shows rapid reduction in target gene expression in responding tumor tissue
24-Apr-2006 -
Lorus Therapeutics Inc. announced publication of data demonstrating decreased expression of the molecular target for its antisense drug, GTI-2040, in a Phase II breast cancer clinical trial. The article titled "Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 ...
cancer therapy
clinical trials
oncology
+1